COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04746183

Helen E Reynolds

livagile@liv.ac.uk

2021-02-09

Recruiting

RCT

Randomized

Sequential assignment

Blind label

multi-center

Treatment

master protocol inclusion criteria: adults (≥18 years) with laboratory-confirmed* sars-cov-2 infection (pcr) ability to provide informed consent signed by study patient or legally acceptable representative women of childbearing potential (wocbp) and male patients who are sexually active with wocbp must agree to use a highly effective method of contraception (as outlined in the protocol) from the first administration of trial treatment, throughout trial treatment and for the duration outlined in the candidate-specific trial protocol after the last dose of trial treatment if any csts are included in the community setting, the cst protocol will clarify whether patients with suspected sars-cov-2 infection are also eligible. standard additional criteria that may be applied per cst protocol: group a (severe disease) 4a. patients with clinical status of grades 4 (hospitalised, oxygen by mask or nasal prongs), 5 (hospitalised, on non-invasive ventilation, or high flow oxygen), 6 (hospitalised, intubation and mechanical ventilation) or 7 (ventilation and additional organ support - pressors, renal replacement therapy (rrt), extracorporeal membrane oxygenation (ecmo)), as defined by the who clinical severity score, 9-point ordinal scale. group b (mild-moderate disease) 4b. ambulant or hospitalised patients with the following characteristics peripheral capillary oxygen saturation (spo2) >94% ra n.b. the cst protocol inclusion criteria will take precedence over the master protocol inclusion criteria. cst-2 inclusion criteria: for the purpose of the eidd-2801 candidate-specific trial the following inclusion criteria have been amended from the master protocol to: 1. male or female ≥ 60 years old or ≥50 years old with at least one well controlled comorbidity: cardiovascular disease, chronic lung disease (e.g. copd, or pulmonary hypertension), immune deficiency (taking the equivalent of 20 mg prednisone daily, chemotherapy, or immune modulating biologic therapies), diabetes (treated with insulin or oral medications), bmi≥30, or hypertension requiring medication with laboratory confirmed sars-cov-2 infection (pcr) . 3. women of childbearing potential (wocbp) and male patients who are sexually active with wocbp must agree to use two effective methods of contraception, one of which should be highly effective (as outlined in the protocol). for women, from the first administration of trial treatment, throughout trial and up to 50 days after the last follow up visit (50 days after day 29) and for men with female partners of child bearing potential, from the first administration until 100 days after last follow up visit (100 days after day 29). 4. group b (mild-moderate disease): ambulant with the following characteristics peripheral capillary oxygen saturation (spo2) >94% ra (nb this differs to the master protocol which also includes hospitalised patients in this group). additional criteria specific to this candidate are: 5. has signs or symptoms of covid-19 that began within 5 days of the planned first dose of study drug. 6. is in generally good health (except for current respiratory infection) and is free of uncontrolled chronic conditions. 7. is willing and able to comply with all study procedures and attending clinic visits through the 4th week. 8. has someone, aged ≥ 16 living in the same household during the dosing period. cst-6 additional inclusion criteria: group a (severe disease). patients with clinical status of grades 5 (hospitalised, oxygen by mask or nasal prongs), 6 (hospitalised, on non-invasive ventilation, or high flow oxygen as defined by the who clinical progression scale (who, 2020)). less than or equal to 14 days from onset of covid-19 symptoms cst-8 inclusion criteria: for the purpose of cst-8, criteria 1 has been amended from the master protocol to: adults (≥18 years) outpatients positive lateral flow test at screening or baseline day 1, who are within 5 days of symptom onset prior to the planned first dose of study drug. criteria 3 has been amended from the master protocol to: women of childbearing potential (wocbp) and male participants who are sexually active with wocbp must agree to use a highly effective method of contraception (as outlined in section 5.5 of the master protocol) for the duration of the treatment and for six weeks following the last dose. additional criteria specific to cst-8 are: initial onset of covid-19 signs/symptoms within 5 days prior to the day of randomisation and at least 1 of the current specified covid-19 signs/symptoms (listed on the nhs website) present on the day of randomisation is willing and able to comply with all study procedures and attending clinic visits master protocol

alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) >5 times the upper limit of normal (uln) stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated glomerular filtration rate <30 ml/min/1.73 m^2) pregnant or breast feeding anticipated transfer to another hospital which is not a study site within 72 hours allergy to any study medication patients taking other prohibited drugs (as outline in cst protocol) within 30 days or 5 times the half-life (whichever is longer) of enrolment patients participating in another ctimp trial n.b. the cst protocol exclusion criteria will take precedence over the master protocol exclusion criteria. cst-2

16

University of Liverpool

18

100

South Africa;United Kingdom

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

600

CST-2 Phase II: To determine the ability of EIDD-2801 to reduce serious complications of COVID-19 including hospitalization, reduction in SAO2<92%, or death.;CST-2 Phase I: To determine the safety and tolerability of multiple ascending doses of EIDD-2801 to recommend dose for phase II.;CST6 Phase I: To determine the maximum safe dose of IV Favipiravir for efficacy evaluation in phase II;CST6 Phase I: To determine the safety and tolerability of multiple doses of IV Favipiravir in patients with COVID-19;CST-8 Phase I: Dose Limiting Toxicities up to and including Day 11;Master Protocol: Dose-finding/Phase I;Master Protocol: Efficacy evaluation/Phase II - Mild to moderate patients (Group B);Master Protocol: Efficacy evaluation/Phase II - Severe patients (Group A)

None

Phase 1/Phase 2

[{"arm_notes": "Phase Ib", "treatment_id": 813, "treatment_name": "Molnupiravir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Phase Ib", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "Phase Ib", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "nan", "treatment_id": 888, "treatment_name": "Nitazoxanide", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 1361, "treatment_name": "Vir-7831", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 1858, "treatment_name": "Vir-7832", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Phase II", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "Phase II", "treatment_id": 888, "treatment_name": "Nitazoxanide", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Phase II", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "nan", "treatment_id": 504, "treatment_name": "Favipiravir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Favipiravir", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "nan", "treatment_id": 813, "treatment_name": "Molnupiravir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2681, "treatment_name": "Molnupiravir+nirmatrelvir+ritonavir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Molnupiravir+nirmatrelvir+ritonavir", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "nan", "treatment_id": 1858, "treatment_name": "Vir-7832", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "VIR-7832", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]